Drugs Acting on Neurotransmitter Systems

A neurotransmitter's life has five stages, and pharmacologically each stage is a lever. Synthesis converts a precursor molecule into the active transmitter using a rate-limiting enzyme (e.g., tyrosine hydroxylase for catecholamines, choline acetyltransferase for acetylcholine). Storage and release package the transmitter into synaptic vesicles via vesicular transporters and expel it into the synaptic cleft when an action potential triggers calcium influx and vesicle fusion. Receptor binding activates postsynaptic (and sometimes presynaptic autoreceptor) receptors, which are either ionotropic (ligand-gated ion channels producing effects in milliseconds) or metabotropic (G-protein-coupled receptors producing slower, longer-lasting effects via second messengers). Reuptake removes transmitter from the cleft using plasma-membrane transporters that recycle it back into the presynaptic terminal. Degradation enzymatically destroys transmitter, either in the cleft (acetylcholinesterase) or intracellularly (monoamine oxidase, catechol-O-methyltransferase). A drug is classified by which stage it hits and whether it increases or decreases net signaling at that stage. An agonist mimics the transmitter at the receptor; an antagonist blocks the receptor without activating it; a reuptake inhibitor prolongs the transmitter's presence in the cleft; an enzyme inhibitor either prevents synthesis (reducing available transmitter) or prevents degradation (increasing it). Because the same five-stage logic applies across chemically unrelated transmitter systems, a student who masters it once can transfer it to acetylcholine, dopamine, serotonin, norepinephrine, GABA, and glutamate without memorizing each system from scratch. The three families surveyed here differ chemically but share this architecture. Acetylcholine is unique in being degraded almost entirely in the synaptic cleft by an enzyme (acetylcholinesterase) rather than being taken back up intact — a fact with major toxicological consequences. Monoamines (dopamine, norepinephrine, serotonin) are cleared predominantly by presynaptic reuptake transporters, making transporter blockade the dominant pharmacological lever for antidepressants and stimulants. Amino acid transmitters (glutamate, GABA) are the workhorses of fast excitatory and inhibitory transmission throughout the brain, and their receptors — ionotropic AMPA/NMDA and GABA-A channels — are targets for anesthetics, anticonvulsants, sedatives, and drugs relevant to excitotoxic neuronal injury.

Cholinergic synapses. Acetylcholine (ACh) is synthesized in the presynaptic terminal from choline and acetyl-CoA by the enzyme choline acetyltransferase (ChAT), then loaded into vesicles by the vesicular acetylcholine transporter (VAChT). Action-potential-triggered calcium influx drives vesicle fusion and ACh release. ACh then acts on two receptor families: nicotinic receptors (ionotropic, found at the neuromuscular junction and in autonomic ganglia) and muscarinic receptors (metabotropic GPCRs, found in the heart, smooth muscle, glands, and CNS). Critically, ACh is not substantially recycled by reuptake; instead it is hydrolyzed in the synaptic cleft by acetylcholinesterase (AChE) into choline and acetate, with choline transported back into the presynaptic terminal for resynthesis. Drugs act at three points. AChE inhibitors (physostigmine, donepezil, and the organophosphate nerve agents sarin and VX) block hydrolysis, causing ACh to accumulate and over-stimulate both nicotinic and muscarinic receptors — therapeutically useful in myasthenia gravis and Alzheimer's disease at low doses, lethal at high doses because of respiratory muscle paralysis and bronchial secretion (the "SLUDGE" muscarinic toxidrome: salivation, lacrimation, urination, defecation, GI distress, emesis). Nicotinic receptor drugs include nicotine itself (agonist), curare and other neuromuscular blockers used in surgical paralysis (antagonists), and the ganglionic blockers used historically for hypertension. Muscarinic drugs include atropine (antagonist, used to counter organophosphate poisoning and to dilate pupils) and pilocarpine (agonist, used in glaucoma).

Monoaminergic synapses. Dopamine and norepinephrine are synthesized from the amino acid tyrosine through a shared pathway: tyrosine → L-DOPA (by tyrosine hydroxylase, the rate-limiting enzyme) → dopamine (by DOPA decarboxylase) → norepinephrine (by dopamine β-hydroxylase, only in noradrenergic neurons) → epinephrine (in adrenal medulla only). Serotonin is synthesized from tryptophan via tryptophan hydroxylase (rate-limiting) and then aromatic amino acid decarboxylase. All three are packaged into vesicles by the vesicular monoamine transporter (VMAT2) and released by calcium-dependent exocytosis. After release, each is cleared from the synapse mainly by a dedicated plasma-membrane reuptake transporter — DAT for dopamine, NET for norepinephrine, SERT for serotonin — with a secondary role for intracellular degradation by monoamine oxidase (MAO-A/B) and, for catecholamines, catechol-O-methyltransferase (COMT). This system offers the richest set of drug targets in psychopharmacology:

Amphetamine deserves special mention because its mechanism differs fundamentally from cocaine's. Cocaine simply blocks the transporter, preventing reuptake of transmitter released normally by exocytosis. Amphetamine is itself taken up into the terminal by DAT, then enters vesicles via VMAT2 and displaces stored dopamine into the cytoplasm; it also drives DAT to run in reverse, exporting dopamine into the synapse independent of action potentials. This is why amphetamine produces a larger, more sustained dopamine surge than cocaine at equivalent transporter occupancy.

Amino acid synapses. Glutamate is the principal excitatory neurotransmitter in the CNS, acting on ionotropic AMPA receptors (fast depolarization) and NMDA receptors (slower, calcium-permeable, and voltage-dependent because of a magnesium block that is relieved only after sufficient depolarization — making NMDA receptors coincidence detectors for pre- and postsynaptic activity, central to long-term potentiation). GABA is the principal inhibitory transmitter, synthesized from glutamate by glutamic acid decarboxylase (GAD), and acting on ionotropic GABA-A receptors (chloride channels producing fast inhibition) and metabotropic GABA-B receptors. Unlike monoamines, glutamate and GABA are cleared largely by astrocytic transporters (EAATs for glutamate) rather than presynaptic reuptake into the releasing neuron itself, with glutamate then converted to glutamine in glia and shuttled back to neurons (the glutamate-glutamine cycle). Drugs here mostly act at the receptor level rather than transporters, because manipulating fast excitatory/inhibitory balance broadly is often more clinically useful than fine-tuning clearance. Benzodiazepines (diazepam, alprazolam) bind an allosteric site at the interface of α and γ subunits of the GABA-A receptor, increasing the frequency of chloride channel opening in response to GABA — they require GABA to be present and have a ceiling effect, making them relatively safe in overdose. Barbiturates bind a different allosteric site, increasing the duration of channel opening, and at high concentrations can open the channel even without GABA — this lack of a ceiling effect makes barbiturate overdose far more dangerous (fatal respiratory depression). Ethanol also potentiates GABA-A receptors (among other targets) and inhibits NMDA receptors, producing combined sedative and dissociative effects. On the glutamate side, ketamine and PCP are NMDA receptor antagonists (blocking the channel pore), producing dissociative anesthesia and, at subanesthetic doses, rapid antidepressant effects under active investigation. Excess glutamate release — as occurs during ischemic stroke when energy failure prevents astrocytic reuptake — causes excessive calcium influx through NMDA receptors, triggering the excitotoxic cascade explored further under Excitotoxicity and Glutamate-Mediated Cell Death.

Otto Loewi's "Vagusstoff" experiment (1921) — proving chemical transmission exists at all. Before drugs targeting neurotransmitter systems could be understood, it had to be established that neurons communicate chemically rather than purely electrically. Loewi electrically stimulated the vagus nerve of an isolated frog heart, slowing its beat, then transferred the perfusion fluid bathing that heart to a second, unstimulated frog heart. The second heart also slowed, proving that the first heart had released a diffusible chemical — which Loewi called Vagusstoff and which was later identified as acetylcholine — rather than transmitting its signal by direct electrical contact. This 1921 experiment (reportedly conceived in a dream, performed the next day) is the foundational demonstration of chemical neurotransmission, without which the entire framework of "drugs acting on neurotransmitter systems" would have no meaning. Loewi shared the 1936 Nobel Prize in Physiology or Medicine with Henry Dale, who independently characterized acetylcholine's actions.

Julius Axelrod and the discovery of reuptake (1950s–60s). For decades after neurotransmitters were identified, it was unclear how their action was terminated. Axelrod used radiolabeled norepinephrine (³H-norepinephrine) injected into animals and traced its fate using autoradiography and tissue fractionation. He found that the labeled norepinephrine was rapidly taken back up into sympathetic nerve terminals rather than being immediately destroyed by enzymes in the cleft, establishing reuptake as the primary mechanism of synaptic clearance for catecholamines. He further showed that cocaine and imipramine (an early tricyclic antidepressant) blocked this reuptake, directly explaining their stimulant and antidepressant effects at the mechanistic level for the first time. This work — for which Axelrod shared the 1970 Nobel Prize with Ulf von Euler and Bernard Katz — is the direct empirical basis for classifying cocaine, amphetamine, and SSRIs as reuptake-system drugs rather than receptor or synthesis-targeting drugs.

Arvid Carlsson and the dopamine-depletion experiments (1957). Carlsson treated rabbits with reserpine, which depletes vesicular monoamine stores by blocking VMAT2, producing profound sedation and Parkinsonian-like immobility. He then administered L-DOPA (the metabolic precursor of dopamine, which unlike dopamine itself crosses the blood-brain barrier) and observed rapid reversal of the reserpine-induced immobility. Using a newly developed fluorescence assay, he showed that L-DOPA restored brain dopamine levels specifically (more than norepinephrine), and that dopamine itself — not just norepinephrine — was a distinct, functionally important neurotransmitter in the brain, concentrated in the basal ganglia. This directly established both (1) that dopamine depletion could produce Parkinsonian symptoms and (2) that precursor loading could reverse it — the rationale that, within a decade, led to L-DOPA becoming the standard treatment for Parkinson's disease in humans. Carlsson received the 2000 Nobel Prize in Physiology or Medicine for this work. Together these three experimental traditions — Loewi's proof of chemical transmission, Axelrod's discovery of reuptake as the clearance mechanism, and Carlsson's demonstration that depleting and restoring a specific monoamine produces and reverses a specific clinical syndrome — form the empirical backbone of the entire framework presented above: that transmitters are synthesized, released, cleared, and can be manipulated at each of these steps with predictable and reversible physiological consequences.

Example 1 — Predicting the interaction of an MAOI and an SSRI. A patient stable on phenelzine (a monoamine oxidase inhibitor, used for treatment-resistant depression) is prescribed fluoxetine (an SSRI) by a second physician unaware of the first prescription. Reasoning mechanistically: phenelzine blocks intracellular degradation of serotonin, dopamine, and norepinephrine, raising cytoplasmic and ultimately synaptic transmitter levels by reducing breakdown. Fluoxetine independently blocks SERT, preventing reuptake and prolonging serotonin's presence in the synapse. These are two different steps in the same pathway (degradation vs. reuptake), so their effects are not merely additive but multiply the amount of serotonin available at the synapse — degradation is blocked so less is destroyed, and reuptake is blocked so what remains stays in the cleft longer and cannot be cleared for eventual metabolism at all. The clinical result is serotonin syndrome: hyperthermia, autonomic instability, myoclonus, and in severe cases death — which is why combining MAOIs with SSRIs is absolutely contraindicated, and why a washout period (typically five weeks for fluoxetine, given its long-acting metabolite norfluoxetine) is required when switching between the two drug classes.

Example 2 — Distinguishing nicotinic vs. muscarinic toxicity in organophosphate poisoning. A farmworker is exposed to an organophosphate pesticide (an AChE inhibitor structurally related to nerve agents) and presents with pinpoint pupils, profuse sweating, salivation, bradycardia, muscle fasciculations, and eventual respiratory failure. Reasoning mechanistically: AChE inhibition causes ACh to accumulate at all cholinergic synapses simultaneously, but the two receptor types produce opposite-looking effects. At muscarinic receptors (heart, glands, smooth muscle, pupil), excess ACh produces the "SLUDGE" syndrome — salivation, bradycardia, bronchoconstriction, miosis — because muscarinic receptors are inhibitory/modulatory GPCRs whose net physiological effect in these tissues is parasympathetic activation. At nicotinic receptors (neuromuscular junction), excess ACh initially causes fasciculations (over-excitation) but then depolarizing blockade and flaccid paralysis, because a nicotinic receptor sitting in a constant flood of agonist cannot repeatedly reset and open — it desensitizes, and the muscle fiber can no longer be driven to fire. Clinically this explains the treatment logic: atropine (a muscarinic antagonist) reverses the SLUDGE symptoms and bradycardia but does nothing for the neuromuscular paralysis, so a second drug, pralidoxime, is given to chemically reactivate AChE itself (by removing the phosphate group from its active site) before the enzyme becomes permanently ("aged") inactivated — restoring nicotinic transmission and rescuing respiratory muscle function.

Arvid Carlsson trained as a physician and pharmacologist in Lund, Sweden, at a time — the mid-1950s — when dopamine was dismissed by most neurochemists as a mere biochemical way-station on the path to norepinephrine, with no independent signaling role of its own. Carlsson's insight was methodological as much as conceptual: he needed a way to measure dopamine directly and specifically in brain tissue, and he adapted a fluorometric assay sensitive enough to distinguish dopamine from its chemical relatives. Working with reserpine — a plant-derived antihypertensive that happened to produce severe sedation and tremor as a side effect — he showed that reserpine's behavioral effects tracked dopamine depletion in the basal ganglia specifically, not norepinephrine depletion elsewhere. He then showed that L-DOPA, and not dopamine itself, could cross the blood-brain barrier and reverse these effects. This chain of reasoning connected a specific molecule, a specific brain region, and a specific movement disorder for the first time — and directly motivated the clinical introduction of L-DOPA for Parkinson's disease by George Cotzias and colleagues in the late 1960s, a treatment still in first-line use today.

Neurology and psychiatry. L-DOPA remains the cornerstone treatment for Parkinson's disease, directly derived from Carlsson's dopamine-depletion model. SSRIs and SNRIs are first-line pharmacotherapy for major depressive disorder and anxiety disorders, and understanding their reuptake mechanism explains their delayed (weeks-long) clinical onset despite immediate transporter blockade — the therapeutic effect depends on slower downstream adaptations such as receptor desensitization and altered gene expression, not the acute rise in synaptic serotonin itself. Antipsychotics, largely dopamine D2 receptor antagonists, are used to manage psychosis, with their side-effect profile (Parkinsonian symptoms, tardive dyskinesia) predictable directly from blocking dopamine transmission in motor circuits.

Emergency medicine and toxicology. Recognizing cholinergic toxidromes (organophosphate/nerve agent poisoning) versus anticholinergic toxidromes (antihistamine or tricyclic overdose — "mad as a hatter, blind as a bat, red as a beet, dry as a bone") allows rapid, mechanism-based triage and antidote selection (atropine plus pralidoxime for the former). Benzodiazepine overdose is managed knowing its ceiling effect makes lethal overdose rare when taken alone, whereas barbiturate or combined alcohol-benzodiazepine overdose is far more dangerous because of GABA-A receptors' non-ceilinged pore-opening at high agonist/allosteric-modulator concentrations.

Anesthesiology. Ketamine's NMDA receptor antagonism explains both its dissociative anesthetic use and its emerging role as a rapid-acting antidepressant, illustrating how a single receptor mechanism can be repurposed across very different clinical indications depending on dose and context.

Addiction medicine. Nicotine replacement therapy, varenicline (a partial nicotinic agonist), and bupropion (a dopamine/norepinephrine reuptake inhibitor) for smoking cessation, along with methadone and buprenorphine for opioid dependence, are all rationally designed based on which step of a neurotransmitter's cycle the abused drug exploits — a foundation directly relevant to the mesolimbic dopamine mechanisms underlying Addiction and the Mesolimbic Reward Circuit.

Agriculture and public health. Organophosphate and carbamate pesticides are AChE inhibitors deliberately engineered for insect nervous systems but toxic to humans at sufficient exposure, making occupational safety limits and antidote stockpiling (atropine, pralidoxime) a direct public-health application of cholinergic pharmacology.

Ask the tutor: How does chronic drug-induced receptor downregulation explain drug tolerance and withdrawal symptoms?